Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service LAA occlusion & loop recorders cases in Montana: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (229 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 7 | 212 | 21% |
| 2020 | 6 | 200 | 22% |
| 2021 | 8 | 347 | 25% |
Left atrial appendage closure and implantable loop recorders: an older, Medicare-heavy population. Professional codes (what the surgeon bills): CPT 33340, 33285; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 92% of the cases CMS names in Montana; 8 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 227 | 10,060+12%/yr | +12%/yr | 2.6 | 33% | 20,000 in 2030+12%/yr |
| Arizona | 106 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Pacemaker, ICD & CRT implantation | 15 | 883+1.5%/yr | +1.5%/yr | 4.71.2× | 0% | 880 in 20300%/yr |
| EP ablation |
LAA occlusion & loop recorders in every state, and its device makers · Every procedure market in Montana · Every state · Compare with California
| 2024 |
| 395 |
| 32% |
| 2025 est. | ≈ 470 | – |
| 2026 est. | ≈ 520 | – |
| 2022 | 9 | 375 | 27% |
| 2023 | 10 | 409 | 30% |
| 2024 | 12 | 395 | 32% |
| 2025 from claims | – | 474 383–557 | 32% |
| 2026 forecast | – | 524 410–658 | 32% |
| 2027 forecast | – | 575 426–760 | 32% |
| 2028 forecast | – | 630 446–870 | 33% |
| 2029 forecast | – | 691 470–991 | 33% |
| 2030 forecast | – | 758 497–1,125 | 34% |
In 2025, 68% inpatient hospital, 32% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~520 | ~360 | ~160 |
| 2027 · ~570 | ~400 | ~180 |
| 2028 · ~630 | ~440 | ~190 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 30% (32% in 2025), inpatient hospital about 69% (68% in 2025).
| 4,739+15%/yr |
| +15%/yr |
| 5.6 |
| 41% |
| 7,950 in 2030+9%/yr |
| Washington | 46 | 2,007+11%/yr | +11%/yr | 2.3 | 2% | 3,420 in 2030+9.3%/yr |
| Colorado | 39 | 1,871+12%/yr | +12%/yr | 3.3 | 4% | 4,220 in 2030+15%/yr |
| Idaho | 16 | 740+15%/yr | +15%/yr | 3.2 | 0% | 1,470 in 2030+12%/yr |
| Oregon | 19 | 718+9.3%/yr | +9.3%/yr | 1.5 | 5% | 1,330 in 2030+11%/yr |
| Utah | 21 | 682+17%/yr | +17%/yr | 2.7 | 16% | 1,130 in 2030+8.9%/yr |
| Nevada | 14 | 673+17%/yr | +17%/yr | 2.0 | 16% | 1,740 in 2030+17%/yr |
| New Mexico | 5 | 431+11%/yr | +11%/yr | 1.6 | 2% | 1,040 in 2030+16%/yr |
| Alaska | 4 | 103+2.1%/yr | +2.1%/yr | 0.8 | 39% | 120 in 2030+2.5%/yr |
| 10 |
| 763+16%/yr |
| +16%/yr |
| 3.61.2× |
| 0% |
| 1,730 in 2030+15%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Boston Scientific leads with 85% of company spending on these surgeons in 2025, −9 pts on 2024.
In 2025, 4 companies reported engagement with Montana’s surgeons worth $5,578 in consulting, speaking, meals and travel tied to these products, about $465 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.